tenapanor tenapanor tenapanor, used in form of tenapanor hydrochloride and sold under the brand name ibsrela, is a treatment for adults with a disease of the gut called irritable bowel syndrome with constipation commonly referred to as ibs-c. tenapanorclinical datatrade namesibsrelaother namestenapanor hydrochlorideahfs/drugs.commonographlicense data us dailymed: tenapanor routes ofadministrationby mouthdrug classnhe3 inhibitorsatc codea06ax08 (who) legal statuslegal status ca: ℞-only us: ℞-only identifiers iupac name n,n'-(10,17,-dioxo-3,6,21,24-tetraoxa-9,11,16,18-tetraazahexacosane-1,26-diyl)bis(benzenesulfonamide) cas number1234423-95-0pubchem cid71587953drugbankdb11761chemspider32056950uniiwyd79216a6keggd11652chemblchembl3304485comptox dashboard (epa)dtxsid40154016 echa infocard100.243.471 chemical and physical dataformulac50h66cl4n8o10s2molar mass1145.04 g·mol−13d model (jsmol)interactive image smiles cn1c(c2=c(c1)c(=cc(=c2)cl)cl)c3=cc(=cc=c3)s(=o)(=o)nccoccoccnc(=o)nccccnc(=o)nccoccoccns(=o)(=o)c4=cc=cc(=c4)5cn(cc6=c5c=c(c=c6cl)cl)c inchi inchi=1s/c50h66cl4n8o10s2/c1-61-31-43(41-27-37(51)29-47(53)45(41)33-61)35-7-5-9-39(25-35)73(65,66)59-15-19-71-23-21-69-17-13-57-49(63)55-11-3-4-12-56-50(64)58-14-18-70-22-24-72-20-16-60-74(67,68)40-10-6-8-36(26-40)44-32-62(2)34-46-42(44)28-38(52)30-48(46)54/h5-10,25-30,43-44,59-60h,3-4,11-24,31-34h2,1-2h3,(h2,55,57,63)(h2,56,58,64)/t43-,44-/m0/s1key:dnhpdwgiximxsa-cxnsmiojsa-n tenapanor is a drug developed by ardelyx, which acts as an inhibitor of the sodium-proton exchanger nhe3. this antiporter protein is found in the kidney and intestines, and normally acts to regulate the levels of sodium absorbed and secreted by the body. when administered orally, tenapanor selectively inhibits sodium uptake in the intestines, limiting the amount absorbed from food, and thereby reduces levels of sodium in the body. this may make it useful in the treatment of chronic kidney disease and hypertension, both of which are exacerbated by excess sodium in the diet. it was approved for medical use in the united states in 2019. the u.s. food and drug administration (fda) considers it to be a first-in-class medication.